Aurobindo Pharma receives USFDA approval for Duloxetine Hydrochloride Delayed Release Capsules

13 Dec 2013 Evaluate

Aurobindo Pharma has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Duloxetine Hydrochloride Delayed-Release Capsules 20mg (base), 30mg (base) and 60mg (base) which was earlier tentatively approved. According to IMS, the market size of the product is estimated to be $5.4 billion for the twelve months ending September 2013.

Duloxetine Hydrochloride Delayed-Release Capsules 20mg (base), 30mg (base) and 60mg (base) are the generic equivalent of Eli Lilly & Company’s Cymbalta Delayed-Release Capsules 20mg (base), 30mg (base) and 60mg (base). Duloxetine Hydrochloride Delayed-Release Capsules are indicated for the treatment of for the treatment of major depressive disorder (MDD) and falls under the Neurological (CNS) therapeutic category. The company now has a total of 188 ANDA approvals (163 Final approvals including 7 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1211.70 -14.45 (-1.18%)
04-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1704.00
Dr. Reddys Lab 1240.15
Cipla 1325.55
Zydus Lifesciences 905.05
Lupin 2194.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×